Financial Performance - The company expects a net profit attributable to shareholders of between 642.28 million and 734.82 million yuan for the first half of 2024, representing a year-on-year increase of 420.70% to 495.72% compared to 123.35 million yuan in the same period last year[8]. - The net profit after deducting non-recurring gains and losses is projected to be between 308.07 million and 400.61 million yuan, reflecting a year-on-year growth of 286.96% to 403.20% from 79.61 million yuan last year[8]. - The basic earnings per share is expected to be between 0.4377 yuan and 0.5008 yuan, compared to 0.0841 yuan per share in the same period last year[8]. Market and Industry Trends - The heparin industry chain's operating environment has improved, with signs of market demand recovery, leading to a positive development trend in the heparin formulation business[9]. - The global demand for heparin API has rebounded, with a significant increase in export volume from China compared to the same period last year, despite a notable decline in export prices due to upstream raw material price drops[10]. Investment Strategy - The company has disposed of part of its equity in HighTide Therapeutics, Inc., which is expected to generate over 250 million yuan in investment income, to be included in non-recurring gains and losses[10]. - The company continues to optimize its external investment strategy to maximize shareholder interests and has made significant progress in its investment portfolio[10]. Business Operations - The CDMO business has continued its recovery, with the company strengthening strategic partnerships with existing clients and exploring new customer groups[4]. - The gross profit margin of formulation products has improved compared to the same period last year, excluding the impact of centralized procurement pricing in the Chinese market[3]. - The company emphasizes maintaining a good pricing system and cost control efficiency in its heparin API business, achieving better average prices than the overall export average from China[10].

Financial Performance - Revenue for 2023 was RMB 5,430,974, a decrease of 24.1% compared to RMB 7,151,039 in 2022[23]. - Profit before tax for 2023 was a loss of RMB 928,334, compared to a profit of RMB 829,851 in 2022[23]. - Basic earnings per share for 2023 was a loss of RMB 0.53, down from a profit of RMB 0.50 in 2022[23]. - Operating income for 2023 was RMB 5,431.0 million, a decrease from RMB 7,151.0 million in 2022, reflecting the impact of the post-epidemic era[29]. - Overall gross profit margin decreased by 14.7 percentage points to 17.3% in 2023, down from 32.0% in 2022[29]. - Loss attributable to shareholders on a consolidated basis was RMB 783.3 million in 2023, compared to a profit of RMB 727.4 million in 2022[29]. - Net operating cash inflow was RMB 398.2 million in 2023, a significant recovery from a net outflow of RMB 756.7 million in 2022[29]. - Gross profit for 2023 decreased by RMB 1,349.3 million to RMB 940.9 million, compared to RMB 2,290.2 million in 2022, with a gross profit margin decline of 14.7 percentage points to 17.3%[79]. - Adjusted gross profit for 2023 was approximately RMB 1,796.3 million, with an adjusted gross profit margin of approximately 33.1%, an increase from 32.5% in 2022[80]. - The loss attributable to equity holders was RMB 783.3 million, while the adjusted profit attributable to equity holders was RMB 387.0 million, down from RMB 841.9 million in 2022[51]. Market and Sales Performance - The Group's enoxaparin finished dose pharmaceutical products maintained stable global sales volumes, holding the second-largest market share in Europe[32]. - In the U.S. market, the Group's enoxaparin products received FDA approval and launched in June 2023, actively increasing market share[32]. - The Group secured first place in China's 8th national volume-based procurement, obtaining contracts from five provinces as primary suppliers[32]. - The Group's marketing strategies in Europe led to steady revenue growth in finished dose pharmaceutical products despite global destocking trends[32]. - The Group expanded its market presence in new regions such as Australia and Ecuador, maintaining a solid second position in international non-European and American markets[32]. - The heparin industrial chain business achieved sales revenue of RMB4,286.3 million, a decrease from RMB5,884.3 million in 2022[54]. - Finished dose pharmaceutical products sales revenue was RMB2,979.0 million, accounting for 54.9% of total revenue, with a gross profit of RMB1,284.6 million, reflecting a 13.4% increase year-on-year[54]. - The heparin API business reported sales revenue of approximately RMB1,307.3 million, down from RMB2,673.8 million in 2022, accounting for 24.1% of total revenue[57]. - The CDMO business generated sales revenue of approximately RMB967.0 million, a decline from RMB1,084.1 million in 2022, with a gross profit margin decreasing to 22.0%[59]. Challenges and Risks - The CDMO business faced challenges with a revenue decline due to the end of key enzyme orders for mRNA COVID-19 vaccines, but recovery efforts in Q4 helped offset losses[33]. - The external environment remains complex and uncertain, with rising interest rates and tightening credit posing challenges to growth[39]. - The Company experienced a fraudulent incident involving approximately EUR 11.74 million, with about EUR 9.74 million (RMB 74.5 million) fraudulently transferred in 2023[44]. - The significant increase in the cost of sales was attributed to the accounting treatment of including impairment losses on inventory in the cost of sales of APIs[79]. - The company faces risks related to market acceptance of its products, which could adversely impact operations and profitability[194]. - The company’s CDMO business is dependent on customer demand for outsourced biologics, and a reduction in spending could materially affect its financial condition[196]. Strategic Initiatives - The Group plans to enhance its heparin business and increase sales volume and market share in various heparin markets while adjusting marketing strategies based on market dynamics[36]. - The Group will focus on improving internal management systems and risk management, collaborating with external experts to optimize internal control management planning in 2024[36]. - The Group aims to leverage its competitive advantages and capitalize on market opportunities to promote long-term sustainable development and maximize shareholder returns[38]. - The Group plans to optimize resource allocation to improve production capacity and meet future business needs more flexibly[74]. - Hepalink aims to explore new business growth points by collaborating with multinational pharmaceutical companies in Europe and the United States[52]. - The Group plans to actively expand the market size and diversify sales distribution in the API business to achieve market share expansion and solidify its leadership position in the API industry[73]. - Hepalink will increase efforts on market expansion of enoxaparin API and promote sales of high-tech, high-quality, and high-value-added enoxaparin API products for steady revenue growth[73]. Governance and Management - The Group has a strong management team with extensive experience across various pharmaceutical sectors, enhancing its strategic capabilities[97]. - The focus on human resources management is crucial for supporting the Group's operational needs and growth[97]. - The Group's strategic committee includes key members who participate in formulating and implementing business strategies[97]. - The Company is committed to maintaining a comprehensive risk management framework to strengthen internal monitoring and risk management capabilities[74]. - The Group has established a framework to safeguard shareholder interests and enhance corporate value through good governance practices[200]. Shareholder Information - The Group's distributable reserves as of December 31, 2023, were RMB 913 million[118]. - The Board has resolved not to declare a final dividend for the year ended December 31, 2023, compared to RMB 1.0 per ten ordinary shares in 2022[111][113]. - The total beneficial ownership of shares by substantial shareholders indicates a concentration of ownership, with the top three shareholders holding over 100 million shares each[170]. - The report highlights compliance with the Securities and Futures Ordinance regarding the disclosure of interests and short positions in shares[168]. - The company has a significant shareholding structure, with major shareholders including Leren Technology and Jintiantu, which together control over 70% of the shares[170]. Future Outlook - The Chairman expressed a cautiously optimistic outlook for business recovery and financial turnaround, emphasizing the importance of cost control for robust financial performance[37]. - The Company is optimistic about future prospects and will continue to implement its existing strategy while observing market trends[74]. - The Group plans to fully utilize the remaining Net Proceeds on or before November 30, 2025[122].

Financial Performance - The company's operating revenue for Q1 2024 was RMB 1,373,251,921.93, representing a 5.55% increase compared to RMB 1,301,021,684.04 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2024 was RMB 155,040,262.39, a significant increase of 133.00% from RMB 66,540,023.25 in the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 157,052,354.18, reflecting a 253.00% increase from RMB 44,491,211.83 year-on-year[3]. - Basic and diluted earnings per share for Q1 2024 were both RMB 0.1057, up 133.33% from RMB 0.0453 in the previous year[3]. - Operating profit for the reporting period reached RMB 196.85 million, a 167.28% increase compared to the same period last year, primarily due to increased gross profit and reduced expenses[9]. - The total profit for the current period is RMB 181,205,852.66, a significant increase of 133.3% compared to RMB 77,557,847.95 in the previous period[24]. - Net profit attributable to the parent company is RMB 155,040,262.39, up from RMB 66,540,023.25, representing a growth of 132.7%[24]. - The operating profit for the current period is RMB 196,847,737.66, compared to RMB 73,649,081.61 in the previous period, indicating an increase of 167.1%[24]. - The total comprehensive income for the current period is RMB 150,135,056.48, which is an increase of 142.3% from RMB 61,856,551.06 in the previous period[26]. Cash Flow - The net cash flow from operating activities reached RMB 880,453,882.15, a remarkable turnaround from a negative cash flow of RMB -213,979,198.80 in the same period last year, marking a 511.47% improvement[3]. - Cash inflow from operating activities is RMB 1,664,646,503.27, down from RMB 1,936,382,607.31, a decrease of 14%[27]. - Cash outflow from operating activities totals RMB 784,192,621.12, a decrease from RMB 2,150,361,806.11, indicating a reduction of 63.5%[28]. - Net cash flow from operating activities is RMB 880,453,882.15, a significant recovery from a negative cash flow of RMB -213,979,198.80 in the previous period[28]. - Cash inflow from investment activities is RMB 441,112,963.21, down from RMB 1,206,613,179.47, a decrease of 63.4%[28]. - Net cash flow from investment activities is RMB 130,688,287.99, a decrease of 83.6% compared to RMB 795,650,734.04 in the previous period[28]. - Cash inflow from financing activities totaled approximately ¥835.83 million, down from ¥1,604.26 million in the previous period, representing a decrease of about 47.9%[29]. - Cash outflow from financing activities amounted to approximately ¥1,506.67 million, compared to ¥1,723.83 million last period, indicating a decrease of about 12.6%[29]. - Net cash flow from financing activities was negative at approximately -¥670.83 million, worsening from -¥119.57 million in the previous period[29]. - The net increase in cash and cash equivalents for the period was approximately ¥342.74 million, down from ¥433.44 million in the previous period[29]. - The ending balance of cash and cash equivalents reached approximately ¥2,108.38 million, an increase from ¥1,753.15 million in the previous period[29]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 18,874,970,670.54, a decrease of 1.71% from RMB 19,203,415,131.24 at the end of the previous year[3]. - Total liabilities decreased to RMB 6,736,457,897.24 from RMB 7,215,037,414.42, reflecting a reduction of about 6.6%[21]. - The company's total equity increased to RMB 12,138,512,773.30 from RMB 11,988,377,716.82, reflecting a growth of approximately 1.3%[22]. - Cash and cash equivalents at the end of the period were RMB 2,225,125,933.99, compared to RMB 1,851,642,224.58 at the beginning of the period, showing an increase of about 20.2%[18]. - Inventory decreased to RMB 6,341,627,515.17 from RMB 6,654,110,787.81, indicating a decline of approximately 4.7%[18]. - Long-term equity investments decreased to RMB 943,735,674.53 from RMB 1,004,045,899.43, a decrease of about 6.0%[19]. - Total operating costs decreased to RMB 1,184,463,117.86 from RMB 1,239,337,824.93, indicating a reduction of about 4.4%[23]. Research and Development - Research and development expenses for Q1 2024 were RMB 35,294,968.25, an increase of 33.11% compared to RMB 26,514,765.57 in the same period last year[8]. - Research and development expenses increased to RMB 35,294,968.25, up from RMB 26,514,765.57, representing a growth of approximately 33.2%[23]. Market Strategy - The company plans to accelerate its sales strategy in New Zealand and Thailand following the approval of its heparin sodium injection in these markets[11]. - The company is focusing on expanding its market share in the heparin sodium formulation business, ranking second in sales in Europe during the reporting period[12]. - The CDMO business has shown significant revenue growth compared to the previous year, driven by the integration of resources and expansion of customer base[13]. - The company aims to enhance its development momentum and fully leverage its competitive advantages to achieve breakthrough growth in 2024[14]. - The focus will be on expanding sales in key overseas markets, particularly in Europe and the United States, while also targeting new non-European and non-American markets[14]. - In the heparin industry chain, the company will continue to prioritize centralized procurement in the Chinese market to drive sales growth[14]. - The company plans to implement a dual-driven platform strategy in its CDMO segment to maximize project value for clients and improve the success rate of ongoing projects[14]. Shareholder Information - The company reported a total of 28,328 common shareholders at the end of the reporting period, with the top two shareholders holding 60.12% of the shares[15]. - Shenzhen Le Ren Technology Co., Ltd. holds 32.31% of the shares, while Xiamen Jintian Soil Investment Partnership holds 27.81%[15]. Financial Incidents - The company experienced a telecom fraud incident involving approximately €11.7 million, with an impact of RMB 15.56 million on pre-tax profit and net profit for 2024[17]. - The actual controller of the company provided an advance payment of RMB 89.81 million to safeguard the interests of the company and its investors[17]. Financial Management - The company is actively managing its financial structure and cost control to balance financial risks and reduce capital costs[11]. - The company will continue to adopt prudent financial and liquidity management to enhance management efficiency and risk control[14]. - The company is committed to maximizing asset value and improving profitability through resource integration and strategic investments[14].

Financial Performance - The company's revenue for Q1 2024 was CNY 1,373,251,921.93, representing a 5.55% increase compared to CNY 1,301,021,684.04 in the same period last year[6]. - Net profit attributable to shareholders was CNY 155,040,262.39, a significant increase of 133.00% from CNY 66,540,023.25 year-on-year[6]. - The net profit after deducting non-recurring gains and losses reached CNY 157,052,354.18, marking a 253.00% increase from CNY 44,491,211.83 in the previous year[6]. - Basic earnings per share rose to CNY 0.1057, reflecting a 133.33% increase from CNY 0.0453 in the previous year[6]. - The net profit for the current period is CNY 154,597,836.94, compared to CNY 65,948,644.12 in the previous period, representing an increase of approximately 134%[36]. - The total comprehensive income for the current period is CNY 150,135,056.48, up from CNY 61,856,551.06 in the previous period, indicating a growth of about 143%[36]. Cash Flow and Liquidity - The net cash flow from operating activities improved to CNY 880,453,882.15, a 511.47% increase compared to a negative cash flow of CNY -213,979,198.80 in the same quarter last year[6]. - Cash and cash equivalents increased to CNY 2,225,125,933.99 from CNY 1,851,642,224.58, a growth of approximately 20.2%[27]. - The cash and cash equivalents at the end of the period reached CNY 2,108,383,601.96, compared to CNY 1,753,147,431.84 at the end of the previous period, marking an increase of approximately 20%[43]. - The company reported cash inflows from investment activities of CNY 441,112,963.21, down from CNY 1,206,613,179.47 in the previous period, reflecting a decrease of about 63%[40]. - The company’s cash outflows from financing activities totaled CNY 1,506,667,399.54, down from CNY 1,723,828,354.57 in the previous period, reflecting a decrease of about 13%[43]. - The company received CNY 826,834,358.22 in cash from borrowings during the current period, compared to CNY 1,517,257,215.11 in the previous period, indicating a decrease of approximately 45%[43]. Operating Costs and Expenses - Total operating costs decreased to CNY 1,184,463,117.86 from CNY 1,239,337,824.93, a reduction of about 4.4%[34]. - The company incurred total operating expenses of CNY 358,344,170.74, a decrease from CNY 1,656,590,949.14 in the previous period, indicating a reduction of approximately 78%[40]. - The company faced a notable increase in other expenses, primarily due to a telecom fraud incident involving its subsidiary Techdow Pharma Italy S.R.L., resulting in an expense of CNY 15,559,523.79[12]. Research and Development - The company's R&D expenses increased by 33.11% to CNY 35,294,968.25, compared to CNY 26,514,765.57 in the same period last year[12]. - Research and development expenses rose to CNY 35,294,968.25 from CNY 26,514,765.57, an increase of approximately 33.1%[34]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,328[16]. - Shenzhen Le Ren Technology Co., Ltd. holds 32.31% of shares, totaling 474,029,899 shares[16]. - Xiamen Jintian Investment Partnership (Limited Partnership) holds 27.81% of shares, totaling 408,041,280 shares[16]. - HKSCC NOMINEES LIMITED holds 15.00% of shares, totaling 220,036,980 shares[16]. - The company has a total of 46,425,600 shares held by Xiamen Water Dripping Stone Investment Partnership (Limited Partnership)[20]. - The company has a total of 40,320,000 shares held by Xiamen Feilai Stone Investment Co., Ltd.[20]. Fraud Incident - The company suffered a telecom fraud involving approximately €11.7 million, impacting net profit by RMB 15.56 million[21]. - The actual controller, Li Li, provided an advance payment of RMB 89,809,600 to safeguard the company's interests[21]. - The company has initiated an independent third-party investigation regarding the fraud incident[21]. Asset and Liability Overview - Total assets at the end of the reporting period were CNY 18,874,970,670.54, a decrease of 1.71% from CNY 19,203,415,131.24 at the end of the previous year[6]. - Total liabilities decreased to CNY 6,736,457,897.24 from CNY 7,215,037,414.42, a reduction of approximately 6.6%[30]. - Shareholders' equity increased to CNY 12,138,512,773.30 from CNY 11,988,377,716.82, reflecting a growth of about 1.3%[33]. - Inventory decreased to CNY 6,341,627,515.17 from CNY 6,654,110,787.81, a decline of about 4.7%[27]. Other Financial Metrics - The company reported a significant increase in fair value gains of 161.07%, amounting to CNY 27,621,985.05, compared to CNY 10,580,213.43 in the previous year[12]. - The company experienced a substantial increase in operating profit, which reached CNY 196,847,737.66, a 167.28% increase from CNY 73,649,081.61 year-on-year[12]. - Net loss from investments was CNY -61,890,173.43, worsening from CNY -13,710,428.46 in the previous year[34]. - Gross profit margin improved, with operating costs at CNY 899,550,310.44 compared to CNY 846,991,799.17, indicating a more efficient cost structure[34].

R&D Investment - R&D investment in 2023 was CNY 289 million, an increase of 31.36% compared to CNY 220 million in 2022, with R&D expenses accounting for 3.44% of revenue, down from 3.65%[2] - Capitalized R&D investment amounted to CNY 4.70 million, a decrease of 47.73% from CNY 8.99 million, with the capitalization ratio dropping to 2.51% from 3.44%[3] Financial Performance - The company's net cash flow from operating activities showed significant discrepancies compared to the net profit for the year[5] - Total investment during the reporting period was CNY 798.69 million, a decrease of 82.15% from CNY 4.48 billion in the same period last year[11] - The fair value of trading financial assets (excluding derivatives) was CNY 1.31 billion, with a net increase of CNY 19 million during the period[8] - The total financial assets at the end of the period amounted to CNY 1.67 billion, with a fair value change of CNY 1.52 billion[13] - The company reported a net profit of approximately 334.53 million yuan for its subsidiary Duople, with total assets of approximately 5.43 billion yuan[36] Investment and Risk Management - The company pledged 100% equity of its subsidiary, Shenzhen Duople Industrial Development Co., Ltd., valued at CNY 280 million, to secure loans[10] - The company reported a significant decrease in derivative investments for hedging purposes during the reporting period[14] - The company is actively involved in securities investments, including various funds and stocks, with notable holdings in TPG Biotech and ORI Healthcare Fund[12] - The company has implemented control measures to manage risks associated with its overseas assets, particularly in the U.S. market[8] - The company plans to strengthen its global supply chain layout and budget management to mitigate the impact of raw material price volatility on operations[41] Market Position and Strategy - The company aims to maintain growth and consolidate its market leadership in the formulation business, with a focus on international development and enhancing product competitiveness through overseas sales strategies[20] - In the Chinese market, the company has seen significant growth in market share due to the initial success of the eighth batch of centralized procurement, positioning it as a new growth driver for the formulation business[20] - The company has extended its heparin industry chain and actively developed CDMO and innovative drug businesses, although it remains heavily reliant on the sales of enoxaparin sodium formulations and raw materials[23] - The success of the CDMO business is largely dependent on the number and scale of service contracts with pharmaceutical and biotechnology companies, benefiting from the growing global biopharmaceutical market[24] - The company aims to achieve new breakthroughs in business while consolidating its existing foundation, demonstrating its professionalism and strategic vision as an industry leader[39] Quality Control and Compliance - The company is committed to increasing quality control and assurance efforts to mitigate product quality risks associated with its complex production processes[22] - The company has established a governance structure that complies with regulatory requirements, ensuring independent operations from its controlling shareholder[30] - The company emphasizes high-quality product production and has a strict quality control system in place[151] - The company is committed to improving internal controls and risk management systems to ensure compliance and operational efficiency[39] Corporate Governance - The company has established a comprehensive governance structure to protect the rights of shareholders and creditors[150] - The company has established a transparent performance evaluation and incentive mechanism for its directors and senior management[59] - The company has appointed Zhang Ping as a non-independent director, and Huang Peng and Yi Ming as independent directors during the reporting period[85] - The company has maintained a competitive salary system for employees, ensuring fairness and market competitiveness[66] Shareholder Dynamics - The total number of shares held by directors and senior management is 15,118,035, accounting for 1.03% of the company's total share capital[69] - The largest shareholder, Shenzhen Le Ren Technology Co., holds 32.31% of shares, totaling 474,029,899 shares[138] - The company has a total of 26,485 common shareholders as of the end of the reporting period, a decrease from 28,325 at the end of the previous month[197] - The company has a diverse shareholder base, including both domestic and foreign investors[199] - The shareholder structure suggests a concentrated ownership, which may impact corporate governance and decision-making[199] Social Responsibility and Sustainability - The company actively participates in social responsibility initiatives, including community development and environmental protection[151] - The company has implemented energy management measures, including replacing regular energy-saving lamps with LED lights[125] Fraud Incident and Regulatory Scrutiny - The company reported a loss of approximately €11.7 million due to a telecom fraud incident involving its wholly-owned subsidiary in Italy[173] - The actual controller of the company, Mr. Li Li, provided an advance payment of RMB 89,809,600 to cover the losses incurred from the fraud[173] - The company has been under scrutiny from the China Securities Regulatory Commission, which issued a corrective action decision on February 2, 2024[174] - The company has established a third-party investigation team to thoroughly investigate the fraud incident[173] - The company has implemented a corrective action plan in response to the regulatory decision, which was approved by the board of directors[174]

监事会同意董事会出具的《关于 2023 年度内部控制审计报告带强调事项段 无保留审计意见涉及事项的专项说明》，并将监督公司董事会和管理层落实相关 整改措施，切实维护公司和全体股东的合法权益。 深圳市海普瑞药业集团股份有限公司 监事会 二〇二四年三月二十八日 深圳市海普瑞药业集团股份有限公司 监事会对《董事会关于 2023 年度内部控制审计报告带强调 事项段的无保留审计意见涉及事项的专项说明》的意见 安永华明会计师事务所（特殊普通合伙）对深圳市海普瑞药业集团股份有限 公司（以下简称"公司"）出具了带强调事项段的无保留意见《内部控制审计报 告》。根据《深圳证券交易所股票上市规则》等相关规定，公司董事会出具了《关 于 2023 年度内部控制审计报告带强调事项段无保留审计意见涉及事项的专项说 明》，现公司监事会就董事会出具的专项说明发表如下意见： ...

Financial Performance - Revenue for the year ended December 31, 2023, was RMB 5,431.0 million, a decrease of 24.1% compared to RMB 7,151.0 million in 2022[2] - The company's loss attributable to equity holders for 2023 was RMB 783.3 million, compared to a profit of RMB 727.4 million in 2022[2] - The company reported a net loss of RMB 802.2 million for the year, compared to a profit of RMB 715.0 million in 2022[4] - The adjusted profit attributable to equity holders, excluding investment losses and inventory impairment, was RMB 387.0 million, down from RMB 841.9 million in 2022[10] - The total revenue for the year 2023 decreased by 24.1% to RMB 5,430.97 million, compared to RMB 7,151.04 million in 2022[23] - The company reported a pre-tax loss of RMB 928,334,000 for the year, influenced by various expenses including financing costs of RMB 228,087,000[50] Revenue Breakdown - The sales revenue from the formulation business was RMB 2,979.0 million, a decline from RMB 3,210.5 million in 2022[2] - The sales revenue from the API business was RMB 1,307.3 million, down from RMB 2,673.8 million in 2022[2] - The CDMO business generated sales revenue of RMB 967.0 million, compared to RMB 1,084.1 million in 2022[2] - The heparin industry chain business generated sales revenue of RMB 4,286.3 million, compared to RMB 5,884.3 million in 2022[12] - The formulation sales maintained stability with revenue of RMB 2,979.0 million, accounting for 54.9% of total revenue, and a gross profit margin increase to 43.1% from 35.3% in 2022[12] - Revenue from the pharmaceutical segment was RMB 2,979,030,000, while API segment revenue was RMB 1,307,343,000, and CDMO services generated RMB 966,952,000[57] Asset and Liability Management - Total non-current assets as of December 31, 2023, amounted to RMB 8,599.1 million, an increase from RMB 8,343.7 million in 2022[6] - Total current assets decreased to RMB 10,604.3 million from RMB 12,472.3 million in 2022[6] - Total current liabilities were RMB 4,986.2 million, down from RMB 5,575.8 million in 2022[6] - The company's net asset value stood at RMB 11,988,377 thousand, a reduction from RMB 12,409,465 thousand in 2022, reflecting a decline of approximately 3.4%[7] - Total assets were approximately RMB 19,203.4 million, with total liabilities of approximately 7,215.0 million, resulting in a debt-to-asset ratio of about 37.6%[36] Market Conditions and Challenges - In 2023, the global heparin market faced significant challenges, with the average export price of heparin dropping to USD 4,805 per kg by October, down from USD 11,779 per kg in July, marking a decline of about 59%[9] - The overall economic environment in 2023 was characterized by high inflation and tightening monetary policies, with global trade expected to decrease by 5% compared to the previous year[8] - China's GDP growth for 2023 was recorded at 5.2%, with quarterly growth rates of 4.5%, 6.3%, 4.9%, and 5.2% respectively[8] Impairments and Losses - The company recorded an inventory impairment provision of RMB 855.4 million due to the significant drop in heparin prices and demand fluctuations[9] - The company recognized goodwill impairment loss of RMB 68.2 million, primarily due to difficulties in the CDMO asset group and a decrease in innovative drug orders[29] - Impairment loss on property, plant, and equipment, and other intangible assets amounted to RMB 44.5 million, related to the AR-301 injection development project[30] - The total impairment loss recognized in the income statement was RMB 61,067,000, with the highest losses in the API segment[53] Strategic Initiatives and Future Plans - The company aims to expand its heparin product sales scale as a primary task for 2024, focusing on enhancing market share and operational efficiency[22] - The company plans to optimize resource allocation in its CDMO business to meet diverse customer project needs and enhance production capacity[21] - The company is actively expanding its international market presence and enhancing its sales network in the U.S. and Europe to seek new growth opportunities[10] - The company plans to continue exploring collaboration opportunities and accelerate the strategic layout of innovative drugs through partnerships[10] - The company will strengthen its market presence in the U.S. by collaborating with strategic partners and leveraging its own sales team[21] Clinical Trials and Product Development - Oregovomab's Phase III clinical trial did not meet its primary endpoint, but data suggests potential benefits for patients over 65 and those with MRSA, prompting further exploration of a second Phase III study[16] - AR-301's global Phase III study did not achieve its primary endpoint, yet showed promising trends in older patients and those with antibiotic-resistant infections, leading to discussions with FDA and EMA for a new study design[17] - RVX-208 has completed Phase III trials and received breakthrough therapy designation from the FDA, aiming to reduce major adverse cardiovascular events in high-risk patients[18] - H1710, an acetyl heparinase inhibitor, is in preclinical stages and has shown significant anti-tumor effects in various models, with IND applications planned for China and the US[19] Governance and Compliance - The board of directors includes four executive directors and three independent non-executive directors, ensuring that independent opinions are represented[79] - The audit committee has reviewed the consolidated annual performance for the year ending December 31, 2023, and confirmed compliance with relevant accounting standards and regulations[84] - Ernst & Young confirmed that the financial figures in the preliminary announcement align with the consolidated financial statements for the year ending December 31, 2023[85]

深圳市海普瑞药业集团股份有限公司 《公司章程》修订对照表（2023 年 11 月） 深圳市海普瑞药业集团股份有限（以下简称"公司"）于 2023 年 11 月 20 日 召开第六届董事会第五次会议，审议通过了《《关于修订<公司章程>及公司部分内 部管理制度的议案》，拟对《公司章程》进行相应的修改，本次章程修订对照表 如下： | 原《公司章程》内容 | 修订后《公司章程》内容 | | --- | --- | | 第一章 总则 | 第一章 总则 | | 第一条 为维护公司、股东和债权人的合法 | 第一条 为维护公司、股东和债权人的合法 | | 权益，规范公司的组织和行为，根据《《中华 | 权益，规范公司的组织和行为，根据《《中华 | | 人民共和国公司法》（以下简称"《《公司 | 人民共和国公司法》（以下简称"《公司 | | 法》"）、《中华人民共和国证券法》（以下简 | 法》"）、《中华人民共和国证券法》（以下简 | | 称"《《证券法》"）、《国务院关于股份有限公 | 称"《《证券法》"）、《境内企业境外发行证券 | | 司境外募集股份及上市的特别规定》（以下 | 和上市管理试行办法》、《上市公司章程指 | ...

监事会议事规则 深圳市海普瑞药业集团股份有限公司 监事会议事规则 第一章 总则 第一条 为明确监事会的职责权限，规范监事会内部机构及运作程序，充分 发挥监事会的监督管理作用，公司根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《上市公司股东大会规则》、《深圳证券交易所股票上市规则》、《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》、《香港联 合交易所有限公司证券上市规则》（以下简称"《香港上市规则》"，"香港联合交 易所有限公司"以下简称"香港联交所"）及其他相关法律、法规规定和《深圳市海 普瑞药业集团股份有限公司章程》（以下简称"《公司章程》"），制定本议事规则。 第二条 公司监事会依照法律、行政法规及《公司章程》的规定履行监督职 责，维护公司及股东的合法权益。 第三条 公司指定专门负责人员协助监事会主席处理监事会日常事务。监事 会主席或公司指定的专门负责人员保管监事会印章。 第二章 监事会职权 第四条 公司监事会由 3 名监事组成，设监事会主席 1 人。包括 2 名股东代 表和 1 名职工代表。监事会中的股东代表由股东大会选举和罢免，职工代表由公 司职工通过职工代表大会 ...

独立董事工作制度 深圳市海普瑞药业集团股份有限公司 独立董事工作制度 第一条 为进一步完善深圳市海普瑞药业集团股份有限公司（以下简称"公 司"）的法人治理结构及公司董事会结构，强化对内部董事及经理层的约束和激 励机制，保护中小股东及利益相关者的利益，促进公司的规范运作，根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立董事管理办法》、 《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》、 《香港联合交易所有限公司证券上市规则》（以下简称"《香港上市规则》"，"香 港联合交易所有限公司"以下简称"香港联交所"）等公司股票上市地有关法律、 行政法规、部门规章和规范性文件以及《深圳市海普瑞药业集团股份有限公司章 程》（以下简称"《公司章程》"）的规定和要求，结合公司实际情况，制定本制 度。 公司董事会下设的薪酬与考核委员会、提名委员会、审计委员会，独立董事 应当过半数并担任召集人。审计委员会由独立董事中会计专业人士担任召集人。 第二条 公司独立董事是指不在公司担任除董事外的其他职务，并与其所受 聘公司及主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影 响其进行独 ...